Dark Matter Blog

JULY 16, 2021

The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. As any good idea tends to have a long life, Ad-IFN is currently in a phase 3 clinical trial in mesothelioma patients.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Alta Sciences

AUGUST 21, 2024

Throughout the summer, I learned the documentation, regulations, and accountability required to perform R&D work in an industrial laboratory. I was greatly inspired by the way Altasciences ensures all processes are rigorously regulated and traceable, as well as the way their integrated services provide clients with a seamless experience.

International 40

International Laboratories Science Molecular Biology 40

The Pharma Data

JANUARY 25, 2021

The AD-SAB will work closely with NervGen as the Company plans its upcoming preclinical studies and clinical trials and in the analyses of the results from these studies. Corey Davis Ph.D., LifeSci Advisors LLC cdavis@lifesciadvisors.com. Follow NervGen on Twitter (@NervgenC) and LinkedIn (NervGen Pharma Corp.)

Disease 40

Disease Clinical Development Molecular Biology Treatment 40

Codon

JUNE 18, 2024

Even after a half-century of molecular biology research, scientists didn’t know until recently how gas vesicles physically trap gas while occluding water. For more than a century, scientists thought of gas vesicles as little more than a natural curiosity and, later, as a way for microbes to regulate buoyancy.

Engineering 70

Engineering Laboratories International Clinical Trials 70

Codon

JUNE 26, 2023

The company behind the latter work, SNIPR BIOME , also recently announced results from a phase I clinical trial. A fifth clinical trial for base editing is now enrolling patients. It’s a phase I/II clinical trial for people with relapsed or refractory T-cell acute lymphoblastic leukemia. coli in mice. It will cost $3.2

DNA 52

DNA Therapies Engineering Clinical Trials 52

Codon

JUNE 26, 2023

The company behind the latter work, SNIPR BIOME , also recently announced results from a phase I clinical trial. A fifth clinical trial for base editing is now enrolling patients. It’s a phase I/II clinical trial for people with relapsed or refractory T-cell acute lymphoblastic leukemia. coli in mice. It will cost $3.2

DNA 52

DNA Therapies Engineering Clinical Trials 52

The Pharma Data

OCTOBER 18, 2020

NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect of nicotinamide riboside (NR) on maintaining telomeres, the protective regions at the end of DNA strands. 19, 2020 10:32 UTC. LOS ANGELES–( BUSINESS WIRE )– ChromaDex Corp.

DNA 52

DNA Molecular Biology Disease Trials 52

Drug Target Review

DECEMBER 12, 2024

Early results for one three-participant trial look good an exciting signal to the field. Any study of the genome is incomplete without considering the epigenomic framework within which genes are read and regulated. Progress in molecular biology and translational science [Internet]. 2024 Jan 1 [cited 2024 Oct 22];185209.

Therapies 59

Therapies DNA Molecular Biology Immune Response 59

Codon

JANUARY 8, 2025

The essay should, at a minimum, touch on three things: Why it’s so difficult to choose genetic targets, why it’s difficult to deliver gene-editing payloads to specific parts of the brain, and why it’s difficult to avoid messing stuff up elsewhere in the body in the process (let alone getting clearance to run clinical trials).

Science 62

Science Vaccine Engineering Disease 62

The Pharma Data

DECEMBER 2, 2020

The Phase III trials that involve 44,000 patients (Pfizer) or 30,000 people (Moderna) aren’t adequate for a simple yes or no response. In normal times, Durbin explained, “Phase I trials typically involve 10 to a couple hundred people. Phase II trials involve hundreds to a few thousand people.

Vaccine 52

Vaccine FDA Molecular Biology Licensing 52

Codon

NOVEMBER 1, 2024

.” However, it isn’t clear that such a superintelligence could even be applied to its full potential in biology today, given the dearth of high-quality datasets needed to train it. Still, many of the bottlenecks slowing biology today are biophysical , rather than computational. Subscribe to Asimov Press.

DNA 116

DNA RNA Molecular Biology Laboratories 116